Bimekizumab Clinical Efficacy Responses Translate into Improvements in Patient Outcomes to Week 48 in Patients With Moderate to Severe Hidradenitis Suppurativa: Results from BE HEARD I&II. J of Skin 2025, 9 (6), s707. https://doi.org/10.25251/fpf9fe87.